Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

E. Budde, Lihua; Assouline, Sarit; H. Sehn, Laurie; J. Schuster, Stephen; Yoon, Sung-Soo; Hyun Yoon, Dok; J. Matasar, Matthew; Bosch, Francesc; Seog Kim, Won; J. Nastoupil, Loretta; W. Flinn, Ian; Shadman, Mazyar; Diefenbach, Catherine; O'Hear, Carol; Huang, Huang; Kwan, Antonia; Li, Chi-Chung; C. Piccione, Emily; C. Wei, Michael; Yin, Shen; L. Bartlett, Nancy

doi:10.1200/jco.21.00931

Public

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

Published in Journal of Clinical Oncology • Dec 16, 2021

Authors:

Lihua E. Budde

Sarit Assouline

Laurie H. Sehn

Abstract

PURPOSE: Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). METHODS: This first-in-human trial (ClinicalTrials.gov identifier: NC...

Subject

Medicine

Refractory (planetary science)

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!